BABA ; sell puts as options on BABA start to trade on Monday; pg 20]; Apple [ AAPL ; pg 20]. Bearish stories: Theravance [ THRX ; pg 14]; agricultural sector [machinery AGCO, CNHI, DE ; fertilizer AGU, CF, MOS, POT ; seeds/chemicals
even become a SIFI ; its bank has had the top 5-yr CD rate for months ; pg 13]; Dow Chemical [ DOW ; pg 16]; Theravance [ THRX ; COPD drug royalty based company after the spinoff of R&D arm TBPH ; it sells COPD drugs through GSK ; pg 18
WASHINGTON, Sept 10 (Reuters) - An federal advisory panel has recommended that the U.S. Food and Drug Administration approve a drug made by GlaxoSmithKline Plc and Theravance Inc to treat chronic...
Sept 6 (Reuters) - An experimental drug to treat chronic obstructive pulmonary disease made by GlaxoSmithKline Plc and Theravance Inc appears to work, but its safety data are not entirely conclusive,...
proposed new business deals, and we're maintaining our fair value estimate as we digest the news in relation to last week's Theravance deal announcement. We're intrigued by Elan's decision to take a page out of Valeant's playbook, focusing on underpenetrated
Theravance THRX reported second-quarter earnings that matched our expectations, and we are keeping our fair value estimate at $29 per share
Elan ELN has announced that it intends to pay $1 billion to Theravance for a 21% stake in its royalty stream from partner GlaxoSmithKline ..... The deal relates to four of the six programs included in Theravance 's 2002 LABA partnership with Glaxo: Relvar Ellipta/Breo
* Drug will compete with AstraZeneca's Symbicort (Updates with FDA comment, side effects)
* Panel votes Breo effective in treating airflow obstruction
April 17 (Reuters) - An advisory panel to the U.S. Food and Drug Administration recommended on Wednesday that the agency approve an experimental treatment for smoking-related lung damage made by...